GlassScriptPhysician profile
Grace L Paley
NPI 1184038986
$4,068.18
in general payments reported to CMS, 2019-2025
22 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $257 · 2021: $186 · 2022: $465 · 2023: $565 · 2024: $833 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,675.81 | 2019-2025 | Ngenuity, Clareon, Argos |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $408.82 | 2019 | |
| Abbvie INC. | $319.94 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $280.70 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $258.23 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $142.10 | 2022-2025 | Cequa |
| Sight Sciences, INC. | $130.64 | 2022-2025 | Omni Surgical System |
| Thea Pharma INC. | $123.61 | 2023-2025 | Iyuzeh |
| Glaukos Corporation | $100.94 | 2022-2024 | Ce-Marked Kxla System |
| Gilead Sciences, INC. | $91.46 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $84.12 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $81.89 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $64.71 | 2024-2025 | Miebo, Xiidra |
| Coopervision INC. | $63.23 | 2024 | Misight Contact Lens |
| Amgen INC. | $48.15 | 2024-2025 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $43.26 | 2025 | Acthar |
| Allergan, INC. | $32.20 | 2021-2022 | |
| Genmab U.S., INC. | $31.20 | 2021 | |
| Rxsight INC | $30.44 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Ani Pharmaceuticals, INC. | $27.14 | 2025 | Purified Cortrophin Gel |
| Carl Zeiss Meditec USA, INC. | $24.83 | 2024 | Clarus |
| Biotissue Holdings INC. | $4.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Paley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.